Swedish Orphan (Sweden) Insiders
| SOBI Stock | SEK 302.40 3.40 1.11% |
Swedish Orphan employs about 1.6 K people. The company is managed by 11 executives with a total tenure of roughly 3631 years, averaging almost 330.0 years of service per executive, having 141.45 employees per reported executive. Breaking down Swedish Orphan's management performance can provide insight into the firm performance.
| Konstantina Karampela Insider Director Operations |
| Christine Wesstrom Insider Head Operations |
Swedish |
Swedish Orphan Management Team Effectiveness
The company has return on total asset (ROA) of 0.0555 % which means that it generated a profit of $0.0555 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1061 %, meaning that it generated $0.1061 on every $100 dollars invested by stockholders. Swedish Orphan's management efficiency ratios could be used to measure how well Swedish Orphan manages its routine affairs as well as how well it operates its assets and liabilities.Swedish Orphan Workforce Comparison
Swedish Orphan Biovitrum is currently regarded as top stock in number of employees category among its peers. The total workforce of Drug Manufacturers - Specialty & Generic industry is at this time estimated at about 115,993. Swedish Orphan claims roughly 1,556 in number of employees contributing just under 2% to equities under Drug Manufacturers - Specialty & Generic industry.
The company has Profit Margin (PM) of 0.14 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.24 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.24. Swedish Orphan Biovitrum Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Swedish Orphan Biovitrum Price Series Summation is a cross summation of Swedish Orphan price series and its benchmark/peer.
Swedish Orphan Notable Stakeholders
A Swedish Orphan stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Swedish Orphan often face trade-offs trying to please all of them. Swedish Orphan's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Swedish Orphan's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Konstantina Karampela | Director Operations | Profile | |
| Christine Wesstrom | Head Operations | Profile | |
| Guido Oelkers | CEO Pres | Profile | |
| Thomas Larsen | Head Relations | Profile | |
| Pablo Mora | Head Access | Profile | |
| Armin MD | Head Affairs | Profile | |
| Philip Wood | Head Haematology | Profile | |
| Anders MD | Head Officer | Profile | |
| Torbjrn Hallberg | G HR | Profile | |
| Daniel Rankin | Head Devel | Profile | |
| Henrik Stenqvist | Chief Officer | Profile |
About Swedish Orphan Management Performance
The success or failure of an entity such as Swedish Orphan Biovitrum often depends on how effective the management is. Swedish Orphan management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Swedish management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Swedish management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 1185 people.
Please note, the imprecision that can be found in Swedish Orphan's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Swedish Orphan Biovitrum. Check Swedish Orphan's Beneish M Score to see the likelihood of Swedish Orphan's management manipulating its earnings.
Swedish Orphan Workforce Analysis
Traditionally, organizations such as Swedish Orphan use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Swedish Orphan within its industry.Swedish Orphan Manpower Efficiency
Return on Swedish Orphan Manpower
| Revenue Per Employee | 10M | |
| Revenue Per Executive | 1.4B | |
| Net Income Per Employee | 1.7M | |
| Net Income Per Executive | 243.5M | |
| Working Capital Per Employee | 913.2K | |
| Working Capital Per Executive | 129.2M |
Additional Tools for Swedish Stock Analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.